Quinoa Effects on Glycemic Index and Satiety

Instituto de Investigación Hospital Universitario La Paz

Status: Completed

Conditions: Overweight

Treatments: Dietary Supplement: Anhydrous Glucose; Dietary Supplement: Quinoa variety 4; Dietary Supplement: Quinoa variety 3; Dietary Supplement: Quinoa variety 1; Dietary Supplement: Quinoa variety 2

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02621502

QUINOA

Details and patient eligibility

About

The purpose of this study is to to assess the glycemic index and the satiating properties of different Quinoa varieties, using a Visual Analogue Scale in a sample of healthy overweight subjects.

Full description

Pilot study to evaluate the glycemic index, and the satiating effect using different Quinoa varieties in a group of healthy overweight subjects.

Enrollment: 8 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Men and women from 18 to 65 years old.
• Body mass index (BMI) ≥25 and <30 kg/m2.
• Adequate cultural level and understanding for the clinical trial.
• Signed informed consent

Exclusion criteria

• Individuals with BMI ≥30 or <25 kg/m2
• Vegetarians or individuals with a fiber intake ≥30 g/day
• Individuals diagnosed with Diabetes Mellitus
• Individuals with dyslipidemia on pharmacological treatment
• Individuals with hypertension on pharmacological treatment
• Smokers or heavy drinking individuals (>2-3 servings/day in men and > 1 serving/day in women (1 serving=1 glass of wine or 1 bottle of beer))
• Individuals with large weight fluctuations or who have undergone in recent months a weight loss diet
• Individuals with gastrointestinal diseases that affect the digestion or the absorption of nutrients
• Individuals receiving at least the preceding 2 months a pharmacological treatment that modifies the lipid profile (for example, statins, fibrates, diuretics, corticosteroids, oral antidiabetic medications)
• Pregnant or breastfeeding women
• Women with menstrual irregularities (absence of menstrual cycle at least 2 months prior)
• Individuals with intense physical activity

Trial design

8 participants in 5 patient groups

Quinoa variety 1

Experimental group

Description:

1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.

Treatment:

Dietary Supplement: Quinoa variety 1

Quinoa variety 2

Experimental group

Description:

1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.

Treatment:

Dietary Supplement: Quinoa variety 2

Quinoa variety 3

Experimental group

Description:

1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.

Treatment:

Dietary Supplement: Quinoa variety 3

Quinoa variety 4

Experimental group

Description:

1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.

Treatment:

Dietary Supplement: Quinoa variety 4

Anhydrous Glucose

Active Comparator group

Description:

1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.

Treatment:

Dietary Supplement: Anhydrous Glucose